Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. — CFSMEATLAS
Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.
Smith, M E Beth, Haney, Elizabeth, McDonagh, Marian et al. · Annals of internal medicine · 2015 · DOI
Quick Summary
This study reviewed 35 clinical trials testing different treatments for ME/CFS to see what actually works. The researchers found that a few treatments showed promise—particularly a drug called rintatolimod for exercise performance, and talking therapies plus graded exercise programs for improving fatigue and daily functioning—but most other treatments tested didn't have enough evidence to prove they help. Overall, doctors still need better studies to know for sure which treatments work best for different patients.
Why It Matters
This is one of the most comprehensive reviews of ME/CFS treatment evidence available, providing patients and clinicians with an honest assessment of what treatments have been studied and what the evidence actually shows. By identifying which treatments have promise and where evidence gaps exist, it guides both clinical practice and future research priorities for a condition that affects over 1 million Americans.
Observed Findings
Rintatolimod showed improvements in some exercise performance measures compared to placebo in 2 trials.
Counseling therapies improved fatigue, function, global improvement, and work impairment in some trials.
Graded exercise therapy showed benefits for fatigue and function compared to no treatment, relaxation, or standard care.
Adverse effects and harms were rarely reported or documented across the 35 trials.
Trials of galantamine, hydrocortisone, IgG, valganciclovir, isoprinosine, fluoxetine, and complementary medicines produced inconclusive results.
Inferred Conclusions
Counseling therapies and graded exercise therapy have the strongest current evidence for improving some outcomes in ME/CFS, though effect sizes remain modest.
Rintatolimod may benefit exercise performance in some patients, but evidence is limited to 2 trials.
Most other pharmacological and supplement-based treatments lack sufficient evidence to recommend or refute their use.
The field critically needs larger, longer, better-designed trials with consistent case definitions and robust adverse event monitoring.
Remaining Questions
Which ME/CFS patient subgroups (defined by biomarkers, symptom severity, or disease subtype) are most likely to benefit from counseling, exercise therapy, or rintatolimod?
What This Study Does Not Prove
This review does not prove any single treatment is definitively effective—most findings were low to moderate strength evidence at best. It cannot determine optimal dosing, duration, or which patient subgroups might benefit most from specific treatments. The heterogeneity of included trials and variations in case definitions mean findings may not apply equally to all ME/CFS patients.